Nat Turner
CEO @ Collectors
New York, United States
Nat Turner is a seed investor at Collectors in New York focused on Health Care and Software. Nat Turner is based out of New York, New York, and is the CEO and Chairman of Collectors. Nat previously worked at OneOncology as a board member. Nat Turner attended the Wharton School of the University of Pennsylvania.
- Total investments:
- 78
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nat Turner invests in
Stages Nat Turner invests in
Countries Nat Turner invests in
Round sizes
Round size
- Seed
- $1.5M–$6.3M
- Series A
- $3M–$25M
- Series B
- $5M–$36M
Investment Focus
Industry
- Health Care 23 (29%)
- Software 20 (26%)
- Medical 12 (15%)
- Artificial Intelligence 7 (9%)
- SaaS 5 (6%)
Stage
- Seed 35 (45%)
- Series A 24 (31%)
- Series B 6 (8%)
- Funding Round 4 (5%)
- Pre-Seed 3 (4%)
Country
- United States 61 (78%)
- China 1 (1%)
- Colombia 1 (1%)
- New Zealand 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CollX
|
CollX (pronounced “collects”) is the fastest way to figure out what your cards are worth. Snap photos of them and instantly get the current market price. The company was founded in 2021 and is headquartered in Haddonfield, New Jersey, United States. | $5.5M / Seed / Feb 22, 2023 | |
Collectors
|
Collectors offers authentication and sale services for high-value collectibles. | $100M / Mar 30, 2022 | |
|
Collectors
|
Collectors offers authentication and sale services for high-value collectibles. | $100M / Private Equity / Mar 30, 2022 | |
Oshi Health
|
Oshi Health is a virtual-first gastroenterology (GI) clinic that diagnoses, treats and remotely monitors digestive (GI) conditions. Patients work with Oshi Health's integrated care team of gastroenterologists and GI-specialized nurse practitioners, registered dietitians, behavioral psychologists and health coaches to determine the root causesof their symptoms and use a personalized care plan that includes medication, dietary interventions and stress/anxiety reduction to get symptoms under control. This yields improved health outcomes, quality of life, satisfaction with care and workplace productivity while reducing overall healthcare cost. | $23M / Series A / Oct 12, 2021 | |
Iterative Scopes
|
Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space. The company was founded in 2017 and is based in Cambridge, Massachusetts. | $30M / Series A / Aug 03, 2021 | |
Iterative Health
|
Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments. | $30M / Series A / Aug 03, 2021 | |
Connie Health
|
Connie Health empowers older Americans to make confident, worry-free healthcare decisions. | $13M / Series A / Jul 28, 2021 | |
Nym
|
Nym transforms revenue cycle management by fully automating the medical coding process. Our engine deciphers clinical language in patient charts and accurately assigns medical charge codes in seconds and with zero human intervention. By automating medical coding with Nym, healthcare providers can improve coding quality while significantlyreducing the time and cost associated with medical coding. This ultimately ensures clinical and administrative teams can spend more time focused on patient care. | $25M / Jul 27, 2021 | |
|
Nym
|
Nym transforms revenue cycle management by fully automating the medical coding process. Our engine deciphers clinical language in patient charts and accurately assigns medical charge codes in seconds and with zero human intervention. By automating medical coding with Nym, healthcare providers can improve coding quality while significantlyreducing the time and cost associated with medical coding. This ultimately ensures clinical and administrative teams can spend more time focused on patient care. | $25M / Series B / Jul 27, 2021 | |
|
Nym
|
Nym transforms revenue cycle management by fully automating the medical coding process. Our engine deciphers clinical language in patient charts and accurately assigns medical charge codes in seconds and with zero human intervention. By automating medical coding with Nym, healthcare providers can improve coding quality while significantlyreducing the time and cost associated with medical coding. This ultimately ensures clinical and administrative teams can spend more time focused on patient care. | $25M / Series A / Jul 27, 2021 | |
| See all 78 investments → | |||
Co-Investors
About Collectors
Collectors offers authentication and sale services for high-value collectibles.
Collectors Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Nat Turner
CEO
|
|||
Jason Harinstein
Chief Financial Officer
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Nat Turner invest in?
Nat Turner invests primarily in Health Care, Software and Medical startups, most often at Seed and Series A stage. Most of the 78 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nat Turner's check size?
Nat Turner typically joins rounds of $1.5M–$6.3M at Seed, $3M–$25M at Series A and $5M–$36M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nat Turner participates in.
When did Nat Turner last invest?
The most recent investment recorded for Nat Turner closed in Feb 2023. Shizune tracks 78 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
